{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:37:46Z","timestamp":1792420666739,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002494"],"award-info":[{"award-number":["UL1TR002494"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jcv.2024.105678","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T16:05:27Z","timestamp":1713801927000},"page":"105678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8836-0881","authenticated-orcid":false,"given":"Priya S.","family":"Verghese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justina","family":"Hathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinath","family":"Chinnakotla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Matas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Henry H.","family":"Balfour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2024.105678_bib0001","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJM198905253202105","article-title":"A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts","volume":"320","author":"Balfour","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2024.105678_bib0002","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2009111188","article-title":"Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation","volume":"21","author":"Smith","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jcv.2024.105678_bib0003","unstructured":"Valcyte (valganciclovir hydrochloride) for oral use package insert 2001 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021304s008,022257s003lbl.pdf."},{"key":"10.1016\/j.jcv.2024.105678_bib0004","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1681\/ASN.0000000000000090","article-title":"A randomized trial of valganciclovir prophylaxis versus preemptive therapy in kidney transplant recipients","volume":"34","author":"Reischig","year":"2023","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jcv.2024.105678_bib0005","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group","volume":"340","author":"Lowance","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2024.105678_bib0006","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1586\/14737167.2014.965157","article-title":"The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation","volume":"14","author":"Reischig","year":"2014","journal-title":"Expert. Rev. Pharmacoecon. Outcomes. Res."},{"issue":"7","key":"10.1016\/j.jcv.2024.105678_bib0007","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/0091270009351884","article-title":"Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis","volume":"50","author":"Vezina","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jcv.2024.105678_bib0008","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jamcollsurg.2016.12.027","article-title":"Outcomes and risk factors for graft loss: lessons learned from 1,056 pediatric kidney transplants at the University of Minnesota","volume":"224","author":"Chinnakotla","year":"2017","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.jcv.2024.105678_bib0009","unstructured":"VALTREX (valacyclovir) for oral use package insert 1995 [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020487s014lbl.pdf."},{"key":"10.1016\/j.jcv.2024.105678_bib0010","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcv.2003.12.010","article-title":"Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients","volume":"30","author":"Piiparinen","year":"2004","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2024.105678_bib0011","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1086\/491740","article-title":"A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis","volume":"192","author":"Balfour","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2024.105678_bib0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jviromet.2017.11.001","article-title":"Results of cytomegalovirus DNA viral loads expressed in copies per millilitre and international units per millilitre are equivalent","volume":"252","author":"Dimech","year":"2018","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2024.105678_bib0013","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jac\/dkv342","article-title":"Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?","volume":"71","author":"Billat","year":"2016","journal-title":"J. Antimicrob. Chemother"},{"key":"10.1016\/j.jcv.2024.105678_bib0014","doi-asserted-by":"crossref","first-page":"e13369","DOI":"10.1111\/ctr.13369","article-title":"A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients","volume":"32","author":"Shaikh","year":"2018","journal-title":"Clin. TransPlant"},{"key":"10.1016\/j.jcv.2024.105678_bib0015","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/INF.0000000000001595","article-title":"Valganciclovir dosing for cytomegalovirus prophylaxis in pediatric solid-organ transplant recipients: a prospective pharmacokinetic study","volume":"36","author":"Peled","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.jcv.2024.105678_bib0016","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.07020714","article-title":"Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation","volume":"10","author":"Reischig","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653224000404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653224000404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T12:53:23Z","timestamp":1715777603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653224000404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":16,"alternative-id":["S1386653224000404"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2024.105678","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2024.105678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105678"}}